Related Experiment Video
Updated: Dec 16, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Calcineurin inhibitors revisited: A new paradigm for COVID-19?
René Hage1, Carolin Steinack1, Macé M Schuurmans1
1University Hospital Zurich, Division of Pulmonology, Zurich, Switzerland; University of Zurich, Faculty of Medicine, Zurich, Switzerland.
Abstract:
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVID-19 are all investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment for COVID-19, based on experiences seen in solid organ transplant recipients who suffered from COVID-19.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Pericarditis III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Acute Kidney Injury II: Pathophysiology

